HIV microbicide trials halted

Wakabi, Wairagala
May 2007
CMAJ: Canadian Medical Association Journal;5/22/2007, Vol. 176 Issue 11, p1569
Academic Journal
The article reports on the investigation for ethical breaches during a Phase III clinical trial of Ushercell, an anti-AIDS gel made by Polydex Pharmaceuticals Ltd. in South Africa. The preliminary results of the trial indicate that the use of cellulose sulfate could lead to increased risk of HIV infection. The Independent Data Monitoring Committee will conduct a detailed review of the data to better understand the findings and determine any implications for other microbicide studies.


Related Articles

  • Framing the social in biomedical HIV prevention trials: a 20-year retrospective. MacQueen, Kathleen M. // Journal of the International AIDS Society;2011 Supplement 2, Vol. 14 Issue Supp 2, p1 

    Biomedical research is critical to identifying effective and safe interventions, such as vaccines, microbicides, male circumcision and antiretrovirals, for prevention. Funding for clinical prevention trials is highly competitive and the benchmarks of success ultimately reduce to quickly...

  • VACCINATION MARKET. Bazell, Robert // New Republic;7/1/91, Vol. 205 Issue 1, p14 

    Reports on the increasing attention given to HIV vaccine research. Factors that triggered increased efforts to discover a vaccine that can protect humans from the HIV virus; Estimated number of people who will be infected with HIV by the end of the 20th century; Rules governing vaccine trials;...

  • Baseline Findings of an HIV Incidence Cohort Study to Prepare for Future HIV Prevention Clinical Trials in Kisumu, Kenya. Chege, Wairimu; Pals, Sherri L.; McLellan-Lemal, Eleanor; Shinde, Sanjyot; Nyambura, Monicah; Otieno, Frederick O.; Gust, Deborah A.; Chen, Robert T.; Thomas, Timothy // Journal of Infection in Developing Countries; 

    Introduction: In an analysis of baseline findings of an HIV incidence cohort study, an assessment was made of HIV prevalence among persons presenting for enrollment and any differences in demographic characteristics between persons not enrolled compared to those enrolled. We also described and...

  • 'Getting to Zero': are there grounds for optimism in the global fight against HIV? Lawn, Stephen D. // Indian Journal of Medical Research;Dec2012, Vol. 136 Issue 6, p895 

    The author focuses on the celebration of World AIDS Day with the goal of achieving zero HIV infections, zero discrimination and zero HIV-related deaths from 2011 through 2015. The goal could be attained by continuing the use of antiretroviral therapy (ART) as part of a strategy of early...

  • HIV: NOW AND THEN.  // Gay Times (09506101);Sep2013, Issue 423, p123 

    The authors discuss the use of Pre Exposure Prophylaxis (PrEP), which involves taking anti-HIV drugs before and after having unprotected sex. PrEP is not available in Great Britain although it is part of a National Health Service (NHS) clinical trial. Arguments by some people that PrEP...

  • Ethics of Ancillary Care in Clinical Trials in Low Income Countries: A Nigerian Case Study. Haire, Bridget G.; Ogundokun, Olusegun // African Journal of Reproductive Health;2014 Special Edition, Vol. 18 Issue 3, p135 

    No abstract available.

  • STARPHARMA REPORTS POSITIVE RESULTS WITH VIVAGEL.  // Worldwide Biotech;Sep2007, Vol. 19 Issue 9, p3 

    The article reports on the result of a clinical trial on topical microbicide Vivagel conducted by Starpharma Holdings Ltd. The results revealed that Vivagel is well-tolerated and safe in men. In addition, it is suitable for further development as a topical microbicide for the prevention of HIV...

  • Microbicide might protect pregnant women from HIV.  // AIDS Alert;Sep2011, Vol. 26 Issue 9, p101 

    The article offers information on the study by Microbicide Trials Network (MTN) which seeks to evaluate the effect of tenofovir, a vaginal microbicide, in pregnant and lactating women to prevent HIV infection.

  • CT sites could learn a lot about community rapport from HIV trials.  // Clinical Trials Administrator;Jun2009, Vol. 7 Issue 6, p61 

    The article deals with the Good Participatory Practice (GPP) guidelines for biomedical HIV prevention trials created by the AIDS Vaccine Advocacy Coalition (AVAC) of New York City and the Joint United Nations Program on HIV/AIDS (UNAIDS). These guidelines explain how investigators should work...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics